CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cellino Biotech, Inc., a preclinical biotechnology company building an autonomous biomanufacturing platform for personalized regenerative medicine, today announced the expansion of its executive leadership team with the addition of Ed Tekeian as Senior Vice President of Engineering. As an experienced engineering leader who has spearheaded the development of products ranging from SaaS applications for 3D printers to an FDA-approved Class II intraoral scanner for dental uses, Tekeian will augment the company’s capabilities to build a scalable biomanufacturing platform for patient-specific regenerative medicines.
“We are thrilled to welcome Ed, who will bring deep multidisciplinary engineering leadership experience, in addition to strong acumen developing products used by hundreds of thousands of patients,” said Matthias Wagner, Co-Founder & Chief Technology Officer, Cellino. “As we continue building a robust platform to enable wide access to regenerative therapies, we look forward to working with him to drive the next phase of our growth.”
“Cellino is harnessing multiple technologies to make patient-specific cells accessible to everyone,” said Ed Tekeian. “I am excited to return to technologies with so much patient impact. I'm honored to be joining such an impressive team.”
Ed Tekeian, Senior Vice President of Engineering
Ed brings more than 30 years of experience in the hardware and software industries, having led mechanical, electrical engineering, software, customer, and manufacturing teams. He is a skilled executive and startup co-founder who has delivered multiple successful product launches across 3D printing, dental devices, and radiosurgery devices for cancer therapy in startup and midsize company settings. Prior to joining Cellino, Ed was the Head of Software at Formlabs, where he led an integrated software team in developing user-facing applications for 3D printing.
Prior to Formlabs, he was the Chief Technology Officer at Kuvée, and before that served in senior engineering roles at Sample 6 Technologies, 3M Health Care, Brontes Technologies (acquired by 3M Corporation for $95M), and Zmed Inc. (acquired by Varian Medical Systems for $35M). Ed holds an MS in Computer Science from Tufts University.
About Cellino Biotech, Inc.
Cellino is a preclinical biotechnology company building an ultra-scalable, autonomous biomanufacturing platform for personalized regenerative medicines. Cellino’s vision is to enable healthier lives worldwide with personalized human cells.
